EL CAJON, Calif.–(BUSINESS WIRE)–PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported the appointment of Darin Zehr to its Board of Directors, effective as of May 1, 2024. Mr. Zehr joins as an independent director and will also serve as a member … [Read more…]

DALLAS–(BUSINESS WIRE)–Pharmaceutical Strategies Group (“PSG”), an EPIC company, has added two significant enhancements to its leadership team aimed at further empowering healthcare payers and driving innovation within the pharmacy benefits industry. The company welcomes Mike Sackett as SVP of Financial Analytics, Procurement, and Consulting Strategy and celebrates the well-deserved promotion of Rebekah Gregg to Chief … [Read more…]

For development and commercialization of a new and unique formulation of liquid stable glucagon for use in a bi-hormonal pump and pump systems CHICAGO–(BUSINESS WIRE)–#GvokeHypoPen–Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has … [Read more…]

Funds Will Allow All Communities to Continue to Be Served and Day-to-day Operations to Continue in the Ordinary Course DALLAS–(BUSINESS WIRE)–Today, Steward Health Care (“the Company”), a national fully integrated value-based healthcare system and the largest physician-led hospital operator in the United States, announced that it has commenced an in-court restructuring process through the filing … [Read more…]

There Were No Differences in RFS Regarding Usage for Chemoablation or Post-Endoscopic Ablation, Tumor Size, Multifocality, or Tumor Location RFS Was 100% in Patients who Received Maintenance therapy vs 61% for Patients Who Did Not Receive Maintenance Therapy PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions … [Read more…]

Innovative, Patient-Friendly Solution for the Rapidly Growing Remote Patient Monitoring and Chronic Care Management Markets TAMPA, Fla.–(BUSINESS WIRE)–Smart Meter, the leading supplier of Cellular Remote Patient Monitoring (RPM)™ solutions, has introduced a new version of the iGlucose, its patented cellular-connected glucose meter used by over 200,000 people with diabetes since 2019. The redesigned model, branded … [Read more…]

New and Recurrent Patients Treated with UGN-102 Achieved Similar Durability of Response Rates (DOR) at 12 months PRINCETON, N.J–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan … [Read more…]

60% Complete Response Rate after JELMYTO Induction 25% of Patients Received a Ureteral Stent PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from a real-world patient cohort review of JELMYTO (mitomycin) for pyelocalyceal … [Read more…]

-A single oral administration of MM120 100 µg met its primary and key secondary endpoints and maintained clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical response rate and a 48% clinical remission rate- -MindMed also presents two new epidemiology studies quantifying the burden of GAD in the … [Read more…]

BURLINGTON, Ontario–(BUSINESS WIRE)–Anaergia Inc. (“Anaergia” or the “Company”) (TSX: ANRG) announced today that there will be an additional delay in the filing of its annual information form for the year ended December 31, 2023, audited annual consolidated financial statements for the year ended December 31, 2023, the related management’s discussion and analysis of financial condition … [Read more…]